Switzerland· 66790001
Juluca
A dolutegravir and rilpivirine product containing dolutegravirum, rilpivirinum, registered in Switzerland and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against BAG Spezialitätenliste (Switzerland) on
Informational only — not a medical device.
Where it is registered
Dolutegravir and rilpivirine is registered in 13 of 19 countries.
Countries holding a registration under ATC J05AR21 (dolutegravir and rilpivirine), each read from that country’s own register.
- This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
- 8 of them publish a price we can compare per daily dose
Dolutegravir and rilpivirine · ATC J05AR21
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
BAG Spezialitätenliste (Switzerland)- Active substance
- dolutegravirum, rilpivirinum
- Manufacturer
- —
- Country
- Switzerland (CH)
- ATC code
- J05AR21
- ATC class
- Dolutegravir and rilpivirine
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- BAG Spezialitätenliste (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680667900016Ds 30 StkCHF 947
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Dolutegravir and rilpivirine in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandJulucaParanova Oy
- CzechiaJULUCAViiV Healthcare BV, Amersfoort
- United StatesJulucaViiV Healthcare Company
- United KingdomJuluca 50mg/25mg tabletsViiV Healthcare UK Ltd
- CanadaJULUCAVIIV HEALTHCARE ULC
- NetherlandsJuluca 50 mg/25 mg, filmomhulde tablettenViiV healthcare B.V.
- NorwayJulucaViiV Healthcare BV (1)
- PolandJulucaViiV Healthcare BV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Juluca
- Liechtenstein · Juluca
- Norway · Juluca
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0866738a-4871-4a45-9c93-95f5d4d213a0 GET /v1/drugs/0866738a-4871-4a45-9c93-95f5d4d213a0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "dolutegravirum 50 mg + rilpivirinum 25 mg",
"valid_from": "2019-02-01",
"limitations": null,
"galenic_form": "Filmtabl 50/25 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2019-02-01",
"self_retention_pct": 10
}See everything about dolutegravir and rilpivirine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.